Alkem Laboratories Ltd - 539523 - Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Manish NarangDesignation :- Company Secretary and Compliance Officer Alkem Laboratories Ltd - 539523 - Disclosure Of Related Party Transactions On A Consolidated Basis Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed disclosures of related party transactions, on a consolidated basis, for the half year ended on 31st March, 2020 in the prescribed format. The same have been published on the website of the Company at www.alkemlabs.com. Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayAlkem Laboratories Ltd 2CINL00305MH1973PLC174201 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: MANISH NARANG Designation: President Legal Company Secretary and Compliance Officer EmailId: manishnarang@alkem.com Name of the Chief Financial Officer: RAJESH DUBEY Designation: President Finance and CFO EmailId: rajeshdubey@alkem.com Date: 25/06/2020 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Alkem Laboratories Ltd - 539523 - Closure of Trading Window
This is to inform you that in terms of Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window will remain closed from 29th June, 2020 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter ended 30th June, 2020 are communicated to the Stock Exchanges. Alkem Laboratories Ltd - 539523 - Compliances-Reg.24(A)-Annual Secretarial Compliance
In terms of Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Annual Secretarial Compliance Report for the period ended 31st March, 2020 issued by Practising Company Secretary. Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Disclosure Under Regulation 30(4) Of Securities Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 As Amended ('SEBI Listing Regulations')
This is to inform you that the Board of Directors of the Company vide Circular Resolution passed today i.e 20th June, 2020 approved the closure of operations of its manufacturing facility i.e Betalactum Block located at Daman. Details required to be submitted under Regulation 30 of SEBI Listing Regulations are enclosed herewith. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Approval For Reclassification Under Regulation 31A Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
This is with reference to our letter dated 25th June, 2019 (the 'Application') wherein we intimated the National Stock Exchange of India Limited and BSE Limited (the 'Stock Exchanges') that the Company had received a request from Mr. Nawal Kishore Singh seeking re-classification from the 'Promoter Group' category to 'Public' category. In terms of the Application submitted by us, we had sought your approval for such re-classification. Pursuant to the provisions of Regulation 31A(8)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform you that the Stock Exchanges, vide their respective emails dated 17th June, 2020, have given their approval for the re-classification of Mr. Nawal Kishore Singh from the 'Promoter Group' category to 'Public' category. A copy of the approval letters received from the Stock Exchanges are enclosed herewith for your reference. Request you to kindly take the same on record.
Buy Alkem Laboraties; target of Rs 2850: Motilal Oswal
Motilal Oswal is bullish on Alkem Laboraties has recommended buy rating on the stock with a target price of Rs 2850 in its research report dated June 06, 2020.
Earnings Call Transcript - Q4FY20 for Alkem Labs
Conference Call with Alkem Laboratories Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Listen to the full earnings transcript. Comments from Sandeep Singh, Managing Director The lockdown resulted in significant delays in transportation starting from March 22. Despite this we saw healthy double digit growth in Q4, and our international business grew 20%+ led by the US which grew 25%. In dollar terms growth was 22% YoY. For the full year India grew 11.9% and crossed Rs. 5000 crore revenue mark. Adjusting for the lockdown growth would have been even higher. As per IQVIA data, during the quarter, the company registered value growth of 8.8% YoY, compared to the Indian Pharmaceutical Market (IPM) growth of 9.6% YoY. For the twelve months ended March 2020, the company's secondary sales grew by 16.9% YoY compared to industry growth of 10.8% YoY. The outperformance during the year was mainly led by the anti-infectives segment in which the company grew at more than 1.5x the therapy growth rate. Also in the vitamins/ minerals/ nutrient segment, the company grew at more than 2x the therapy growth rate. In the chronic therapy segments like neuro / CNS, cardiac, anti-diabetes and derma, the company continued to grow significantly ahead of the therapy growth rate, thereby gaining market share and improving its market ranking. This outperformance was driven by the company's strong brands, effective sales and marketing strategies, robust supply chain and distribution network and contribution from new product launches. During the quarter we had two launches in the US market and over the entire year 14 new launches in the US. US grew 16% YoY and crossed key dollar milestones. Our EBITDA margin expanded by 220 bps YoY. Our focus on cost containment, better productivity and higher capacity utilization will be key drivers for EBITDA margins. We invested Rs. 470 crore in R&D.; We received 22 approvals in our ANDAs with 6 tentative approvals as part of the list. All our six manufacturing facilities in India have received EIRs as of current date. We continue to invest in standards for these facilities. We have observed an overall slowdown in new prescription generation, shutdown of OPDs and slowing of elective treatment. We expect that to continue until the lockdowns are lifted. While FY21 has started on a challenging note due to COVID-19, we are positive that the inherent business strengths that we have built over the years in terms of strong brands, marketing and distribution infrastructure and H&U; investments, will help us to navigate through these testing times and deliver a sustainable and a profitable growth. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith press release and analyst presentation on Q4FY20 and FY20 earnings and business updates and the same will be uploaded on the website of the Company. Kindly take note of the same